MAPT and amyloidosis: Collectively, our studies supported the multi‐modal mechanisms of action of our new HDAC6i PB118 in attenuating AD pathology, including reducing amyloid pathology by increasing Aβ uptake and lowering Aβ generation, reducing tau phosphorylation, improving Ac‐α‐tubulin and microtubule network, as well as reducing inflammatory events associated with AD.